Drug Trial Radar · NCT05523947
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
147
Planned (sponsor's estimate)
Start
Aug 26, 2022
Primary completion
Mar 31, 2028
Study completion Apr 30, 2028
Sponsor
- Lead sponsor
- Yuhan CorporationIndustry
- Sponsor type
- Industry
- First posted
- Sep 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This first-in-human study will be counducted to evaluate the safety, tolerability, pharmacokinetics (PK) and anti-tumor activity of YH32367 in Patients with HER2-Positive Locally Advanced or Metastatic Solid Tumors.
Conditions
- HER2-Positive Solid Tumor
Interventions
YH32367Drug
Dose Escalation Part: 8 Cohorts. In this part, approximately 30 patients will be enrolled and patients are assigned to receive YH32367 at a starting dose and the dose being escalated/de-escalated in adjacent dose cohorts will be up to Dose level 8. Dose Expansion Part: 2 Cohorts(Cohort 1: Biliary tract cancer, Cohort 2: Solid tumors). The part will consist of multiple cohorts in patients who were treated with at least 1 prior gemcitabine- and/or cisplatin-based therapy, HER2 positive biliary tract cancer(Cohort 1); in patients who were treated with all available standard therapies and have no available options, HER2 positive solid tumor malignancies other than breast and gastric or gastroesophageal junction adenocarcinoma and biliary tract cancer(Cohort 2). Each cohort will enroll approximately 75 and 40 patients, respectively.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-emergent adverse events (TEAEs) up to Day 21Time frame: in dose escalation part, an average of 21 days
- Objective Response Rate (ORR)Time frame: through dose expansion part completion, approximately 2.5 year
Locations
19 sites in 3 countries. Site status is shown where the registry gives one.
Dana Farber Cancer Institute
Boston, Massachusetts · Withdrawn
Vanderbilt Ingram Cancer Center
Nashville, Tennessee · Recruiting
Southern Oncology Clinical Research Unit
Adelaide, Australia · Terminated
Austin Health
Melbourne, Australia · Withdrawn
Breast Cancer Research Centre - WA
Perth, Australia · Withdrawn
Blacktown Hospital
Sydney, Australia · Recruiting
Gachon Gil University Medical Center
Incheon, South Korea · Recruiting
Korea University Anam Hospital
Seoul, South Korea · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Severance Hospital, Yonsei University Health System
Seoul, South Korea · Recruiting
Asan Medical Center
Seoul, South Korea · Recruiting
Samsung Medical Center
Seoul, South Korea · Recruiting
The Catholic University of Korea, St. Mary's hospital
Seoul, South Korea · Recruiting
Ulsan University Hospital
Ulsan, South Korea · Recruiting
CHA Bundang Medical Center
Seongnam-si, Gyeonggi-do, South Korea · Recruiting
Catholic University of Korea St. Vincent's Hospital
Suwon, Gyeonggi-do, South Korea · Recruiting
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea · Recruiting
Gyeongsang National University Hospital
Jinju, Gyeongsangnam-do, South Korea · Recruiting
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.